Drugs / DP CD8 TIL KD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05902520 | Jun 2023 → Dec 2026 expected | colorectal cancer, female reproductive organ cancer, head and neck squamous cell carcinoma, lung cancer +2 | AgonOx, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DP CD8 TIL KD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05902520 ↗ |
| Action | Deplete | “autologous tumor cell killing” NCT05902520 ↗ |
| Route | Intravenous | “intravenous infusion” NCT05902520 ↗ |